Cargando…

The Risk of Endometrial Cancer and Uterine Sarcoma Following Endometriosis or Pelvic Inflammatory Disease

SIMPLE SUMMARY: It was revealed in the present population-based cohort study that patients with endometriosis had a significantly increased risk of uterine corpus cancer than did propensity score-matched controls. Moreover, it was found that patients with endometriosis were susceptible to not only e...

Descripción completa

Detalles Bibliográficos
Autores principales: Huang, Jing-Yang, Ma, Kevin Sheng-Kai, Wang, Li-Tzu, Chiang, Cho-Han, Yang, Shun-Fa, Wang, Chun-Hao, Wang, Po-Hui
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2023
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9913480/
https://www.ncbi.nlm.nih.gov/pubmed/36765791
http://dx.doi.org/10.3390/cancers15030833
_version_ 1784885437935910912
author Huang, Jing-Yang
Ma, Kevin Sheng-Kai
Wang, Li-Tzu
Chiang, Cho-Han
Yang, Shun-Fa
Wang, Chun-Hao
Wang, Po-Hui
author_facet Huang, Jing-Yang
Ma, Kevin Sheng-Kai
Wang, Li-Tzu
Chiang, Cho-Han
Yang, Shun-Fa
Wang, Chun-Hao
Wang, Po-Hui
author_sort Huang, Jing-Yang
collection PubMed
description SIMPLE SUMMARY: It was revealed in the present population-based cohort study that patients with endometriosis had a significantly increased risk of uterine corpus cancer than did propensity score-matched controls. Moreover, it was found that patients with endometriosis were susceptible to not only endometrial cancer, but also uterine sarcoma. On the contrary, patients with pelvic inflammatory disease did not exhibit an apparent risk of uterine cancer. Overall, endometriosis, but not pelvic inflammatory disease, was an independent risk factor for both endometrial cancer and uterine sarcoma. ABSTRACT: The relationship between uterine corpus cancer and endometriosis was conflicting. We aimed to determine the risk of uterine cancer in patients with endometriosis or pelvic inflammatory disease (PID). In this population-based cohort study, a total of 135,236 females with endometriosis (n = 20,510) or PID (n = 114,726), as well as 135,236 age-matched controls, were included. Cox regression models estimated the risk of uterine cancer in each group. Sub-outcomes of risk for uterine corpus cancer included endometrial cancer and uterine sarcoma were analyzed. An age subgroup analysis was performed to determine the moderator effect of age. A landmark analysis depicted the time varying effect of endometriosis and PID. A propensity score matching analysis was conducted to validate the findings. Patients with endometriosis had significantly higher risk of endometrial cancer (adjusted hazard ratio, aHR = 2.92; 95% CI = 2.12–4.03) and uterine sarcoma (aHR = 5.83; 95% CI = 2.02–16.89), while PID was not associated with the risk of uterine cancer. The increased risk of uterine cancer in patients with endometriosis persisted after propensity score matching (aHR = 2.83, 95%CI = 1.70–4.71). The greatest risk of endometrial cancer occurred in patients who had endometriosis for 37 to 60 months (adjusted relative risk, aRR = 9.15, 95% CI = 4.40–19.02). Females aged 12 to 35 years were at the greatest risk of endometriosis-associated uterine cancer (RR = 6.97, 95% CI = 3.41–14.26). In conclusion, patients with endometriosis were at great risk of uterine cancer, including endometrial cancer and uterine sarcoma, compared with propensity score-matched populations and compared with patients of PID. Younger females with endometriosis and patients who had endometriosis for three to five years were at the greatest risk of endometriosis-associated uterine cancer.
format Online
Article
Text
id pubmed-9913480
institution National Center for Biotechnology Information
language English
publishDate 2023
publisher MDPI
record_format MEDLINE/PubMed
spelling pubmed-99134802023-02-11 The Risk of Endometrial Cancer and Uterine Sarcoma Following Endometriosis or Pelvic Inflammatory Disease Huang, Jing-Yang Ma, Kevin Sheng-Kai Wang, Li-Tzu Chiang, Cho-Han Yang, Shun-Fa Wang, Chun-Hao Wang, Po-Hui Cancers (Basel) Article SIMPLE SUMMARY: It was revealed in the present population-based cohort study that patients with endometriosis had a significantly increased risk of uterine corpus cancer than did propensity score-matched controls. Moreover, it was found that patients with endometriosis were susceptible to not only endometrial cancer, but also uterine sarcoma. On the contrary, patients with pelvic inflammatory disease did not exhibit an apparent risk of uterine cancer. Overall, endometriosis, but not pelvic inflammatory disease, was an independent risk factor for both endometrial cancer and uterine sarcoma. ABSTRACT: The relationship between uterine corpus cancer and endometriosis was conflicting. We aimed to determine the risk of uterine cancer in patients with endometriosis or pelvic inflammatory disease (PID). In this population-based cohort study, a total of 135,236 females with endometriosis (n = 20,510) or PID (n = 114,726), as well as 135,236 age-matched controls, were included. Cox regression models estimated the risk of uterine cancer in each group. Sub-outcomes of risk for uterine corpus cancer included endometrial cancer and uterine sarcoma were analyzed. An age subgroup analysis was performed to determine the moderator effect of age. A landmark analysis depicted the time varying effect of endometriosis and PID. A propensity score matching analysis was conducted to validate the findings. Patients with endometriosis had significantly higher risk of endometrial cancer (adjusted hazard ratio, aHR = 2.92; 95% CI = 2.12–4.03) and uterine sarcoma (aHR = 5.83; 95% CI = 2.02–16.89), while PID was not associated with the risk of uterine cancer. The increased risk of uterine cancer in patients with endometriosis persisted after propensity score matching (aHR = 2.83, 95%CI = 1.70–4.71). The greatest risk of endometrial cancer occurred in patients who had endometriosis for 37 to 60 months (adjusted relative risk, aRR = 9.15, 95% CI = 4.40–19.02). Females aged 12 to 35 years were at the greatest risk of endometriosis-associated uterine cancer (RR = 6.97, 95% CI = 3.41–14.26). In conclusion, patients with endometriosis were at great risk of uterine cancer, including endometrial cancer and uterine sarcoma, compared with propensity score-matched populations and compared with patients of PID. Younger females with endometriosis and patients who had endometriosis for three to five years were at the greatest risk of endometriosis-associated uterine cancer. MDPI 2023-01-29 /pmc/articles/PMC9913480/ /pubmed/36765791 http://dx.doi.org/10.3390/cancers15030833 Text en © 2023 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).
spellingShingle Article
Huang, Jing-Yang
Ma, Kevin Sheng-Kai
Wang, Li-Tzu
Chiang, Cho-Han
Yang, Shun-Fa
Wang, Chun-Hao
Wang, Po-Hui
The Risk of Endometrial Cancer and Uterine Sarcoma Following Endometriosis or Pelvic Inflammatory Disease
title The Risk of Endometrial Cancer and Uterine Sarcoma Following Endometriosis or Pelvic Inflammatory Disease
title_full The Risk of Endometrial Cancer and Uterine Sarcoma Following Endometriosis or Pelvic Inflammatory Disease
title_fullStr The Risk of Endometrial Cancer and Uterine Sarcoma Following Endometriosis or Pelvic Inflammatory Disease
title_full_unstemmed The Risk of Endometrial Cancer and Uterine Sarcoma Following Endometriosis or Pelvic Inflammatory Disease
title_short The Risk of Endometrial Cancer and Uterine Sarcoma Following Endometriosis or Pelvic Inflammatory Disease
title_sort risk of endometrial cancer and uterine sarcoma following endometriosis or pelvic inflammatory disease
topic Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9913480/
https://www.ncbi.nlm.nih.gov/pubmed/36765791
http://dx.doi.org/10.3390/cancers15030833
work_keys_str_mv AT huangjingyang theriskofendometrialcanceranduterinesarcomafollowingendometriosisorpelvicinflammatorydisease
AT makevinshengkai theriskofendometrialcanceranduterinesarcomafollowingendometriosisorpelvicinflammatorydisease
AT wanglitzu theriskofendometrialcanceranduterinesarcomafollowingendometriosisorpelvicinflammatorydisease
AT chiangchohan theriskofendometrialcanceranduterinesarcomafollowingendometriosisorpelvicinflammatorydisease
AT yangshunfa theriskofendometrialcanceranduterinesarcomafollowingendometriosisorpelvicinflammatorydisease
AT wangchunhao theriskofendometrialcanceranduterinesarcomafollowingendometriosisorpelvicinflammatorydisease
AT wangpohui theriskofendometrialcanceranduterinesarcomafollowingendometriosisorpelvicinflammatorydisease
AT huangjingyang riskofendometrialcanceranduterinesarcomafollowingendometriosisorpelvicinflammatorydisease
AT makevinshengkai riskofendometrialcanceranduterinesarcomafollowingendometriosisorpelvicinflammatorydisease
AT wanglitzu riskofendometrialcanceranduterinesarcomafollowingendometriosisorpelvicinflammatorydisease
AT chiangchohan riskofendometrialcanceranduterinesarcomafollowingendometriosisorpelvicinflammatorydisease
AT yangshunfa riskofendometrialcanceranduterinesarcomafollowingendometriosisorpelvicinflammatorydisease
AT wangchunhao riskofendometrialcanceranduterinesarcomafollowingendometriosisorpelvicinflammatorydisease
AT wangpohui riskofendometrialcanceranduterinesarcomafollowingendometriosisorpelvicinflammatorydisease